Apellis Pharmaceuticals

Apellis Pharmaceuticals, established in 2009, is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutic compounds for severe autoimmune diseases. Its core strategy centers on complement immunotherapy, specifically targeting the inhibition of the complement system at the C3 level, a critical pathway in numerous inflammatory and autoimmune conditions. The company operates within the Pharmaceuticals and Healthcare sectors, focusing on innovative treatments that address unmet medical needs.

With a workforce of 500-1,000 employees distributed across 6 locations, Apellis Pharmaceuticals maintains a significant operational footprint. Learn about Apellis Pharmaceuticals' global headquarters for detailed insights into its primary base of operations. The company's commitment to advancing patient care is reflected in its dedicated team; Meet Apellis Pharmaceuticals' team to discover the leadership driving its scientific and clinical endeavors. Trading under the NASDAQ ticker APLS, the company is positioned within a competitive landscape of biopharmaceutical innovators.

Apellis Pharmaceuticals reported a substantial revenue of $1,105.3M, underscoring its commercial progress and investment capacity. This financial strength supports its ongoing research and development of groundbreaking therapies. The company has a history of significant funding, including multiple rounds that have fueled its clinical pipeline. Explore financial highlights to gain a deeper understanding of its fiscal performance, funding history, and market valuation. Its strategic focus on complement inhibition aims to transform the treatment paradigm for debilitating diseases.